Abstract:Asthma is a heterogeneous lung disease, usually characterised by chronic airway inflammation. Although evidence-based treatments are available in most countries, asthma control remains suboptimal, and asthma-related deaths continue to be an ongoing concern. Generally, it is believed that between 50 to 75% of patients with asthma can be considered as having mild asthma.Previous versions of Global Initiative for Asthma (GINA) suggested that mild asthma in adults can be well managed with either reliever medications, for example, short-acting beta2 agonists (SABA) alone or with the additional use of controllers such as regular low-dose inhaled corticosteroids (ICS). Given the low frequency or non-bothersome nature of symptoms in mild asthma, patients' adherence towards their controller medications, especially to ICS is usually not satisfactory. Such patients often rely on SABA alone to relieve symptoms, which may contribute to SABA over-reliance. Overuse of relievers such as SABAs has been associated with poor asthma outcomes, such as exacerbations and even deaths. The new GINA 2019 asthma treatment recommendations represent significant shifts in asthma management at Steps 1 and 2 of the 5 treatment steps. The report acknowledges an emerging body of evidence suggesting the non-safety of SABAs overuse in the absence of concomitant controller medications, therefore does not support SABA-only therapy in mild asthma and has included new off-label recommendations such as symptom-driven (as-needed) low dose ICS-formoterol and "low dose ICS taken whenever SABA is taken".The GINA 2019 report highlights significant updates in mild asthma management and these recommendations represent a clear deviation from decades of clinical practice mandating the use of symptom-driven SABA treatment alone in those with mild asthma. While the new inclusions of strategies such as symptom-driven (as-needed) ICS-formoterol and "ICS taken whenever SABA is taken" are based on several key trials, data in this context are still only emergent data, with clear superiority of as needed ICS-formoterol combinations over maintenance ICS regimens yet to be established for valid endpoints. Nevertheless, current and emerging data position the clinical asthma realm at a watershed moment with imminent changes for the way we manage mild asthma likely in going forward.

The pharmacological management of asthma in adults: 2023 update

Update on Asthma Management Guidelines

The management of asthma and chronic obstructive pulmonary disease: current status and future perspectives

Treatment strategies for asthma: reshaping the concept of asthma management

It is time to change the way we manage mild asthma: an update in GINA 2019

Pharmacogenetic and pharmacogenomic considerations of asthma treatment

Reshaping respiratory care: potential advances in inhaled pharmacotherapy in asthma

Novel drug targets for asthma and COPD: lessons learned from in vitro and in vivo models

New developments in asthma therapeutics

The global initiative for asthma guidelines (2019): change in the recommendation for the management of mild asthma based on the SYGMA-2 trial - A critical appraisal

Pharmacology and Therapeutics of Bronchodilators Revisited

New developments in anti‐asthma drugs

Maintenance Therapy for Children and Adolescents with Asthma: Guidelines and Recommendations from the Emilia-Romagna Asthma (ERA) Study Group

Principles of asthma treatment and appropriate use of new drugs

New perspectives in asthma treatment

Currently Available Inhaled Therapies in Asthma and Advances in Drug Delivery and Devices

New Advances and Potential Therapies for the Treatment of Asthma

Future treatment for asthma

New therapies and management strategies in the treatment of asthma: patient-focused developments

Novel strategies for the treatment of asthma

Management of asthma exacerbations in the paediatric population: a systematic review